Kiniksa Pharmaceuticals Provides Corporate Update

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"image","alt":"Kiniksa Pharmaceuticals International, Plc","displaySize":"","headline":null,"caption":"Kiniksa Pharmaceuticals International, Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":207,"url":"https://media.zenfs.com/en/globenewswire.com/84bc4259d2877b369755dfd109eaa0a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wfBd0ZwknGs8QtzbckR3vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/84bc4259d2877b369755dfd109eaa0a5","width":300,"height":207}},"lazy":false},{"type":"text","content":"– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – ","length":405,"tagName":"p"},{"type":"text","content":"LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today provided a corporate update.","length":294,"tagName":"p"},{"type":"text","content":"“IL-1α & IL-1β inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis. As of the end of 2025, approximately 18% of the multiple recurrence population was actively on ARCALYST therapy. In addition to driving further uptake in this group, we are well-positioned to expand our reach in the broader population of first recurrence patients,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We are also advancing KPL-387 in recurrent pericarditis, which we believe could expand the IL-1α & IL-1β inhibition market by potentially enabling monthly self-administration with a liquid formulation. We are enrolling and dosing patients in the Phase 2 dose-focusing portion of the Phase 2/3 trial, with data expected in the second half of 2026. In addition, we plan to commence a Phase 1 first-in-human trial with KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist, by the end o...

More updates from Kiniksa Pharmaceuticals International, Plc